EUROAPI is a European manufacturer and development partner specializing in active pharmaceutical ingredients (APIs) for the global pharmaceutical and biotechnology industries. Formed from Sanofi’s historical API activities and listed on Euronext Paris, the company provides a broad portfolio of generic APIs and offers custom development and manufacturing (CDMO) services under Good Manufacturing Practice (GMP) standards.
EUROAPI’s capabilities span complex small-molecule synthesis and biotechnology-derived APIs, including advanced modalities such as peptides and oligonucleotides. Its integrated model covers process research and development, scale-up, industrial production, and regulatory support. The company operates multiple production and R&D sites across Europe, notably in France, Germany, Hungary, Italy, and the United Kingdom, supplying customers worldwide with pharmaceutical-grade ingredients across therapeutic areas.
The FOCUS-27 plan aims to boost competitiveness with €110-120M restructuring costs, €350-400M CAPEX, and €75-80M annual EBITDA by 2027, focusing on high-value APIs and strategic sites.
